TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Soda Tax Uncaps Fight Makers and sellers of soda and other sweet drinks have intensified a fight against proposed taxes on their products, as a growing number of cities and states are weighing the measures to help fill depleted coffers. online.wsj.com |
Women Succeeding with Epilepsy - Video Women Help Women Live and Cope with a Chronic Medical Condition in the Family feedproxy.google.com |
Arena's Obesity Drug Likely to Pass FDA Panel With Flying Colors Rockford Coscia submits:This year a trio of obesity drugs has stormed onto the stage and they will soon face their respective FDA decisions. The trio consists of Vivus’ (VVUS) Qnexa, which was already voted down by an FDA panel, Arena’s (ARNA) Lorcaserin, and Orexigen’s (OREX) Contrave. Following Qnexa’s jilting by FDA panel, many investors piled into Arena as lorcaserin’s side effect profile appeared the most benign of the three. Lorcaserin faces its own FDA panel on September 16. While I’m guessing that multiple issues will be discussed – including potential off-label use with fentermine – one of the issues likely to be addressed is the potential of valvulopathy in long-term use of lorcaserin. There is very good reason to believe, however, that these concerns will be little more than a distraction on the way to lorcaserin’s approval.Complete Story » seekingalpha.com |
Why You Forget Birthdays Jeremy Singer-Vine summarizes new medical findings on memory, stroke, breastfeeding, obesity, weight loss and smoking. online.wsj.com |
Genentech's Herceptin Wins U.S. OK in Stomach Cancer WASHINGTON – More than a decade after first gaining approval as a breast cancer treatment – and the first-ever drug approved with a companion diagnostic – Genentech Inc.'s targeted therapy Herceptin (trastuzumab) plus chemotherapy won the FDA's OK Wednesday night to treat HER2-positive metastatic stomach cancer in adults who have not received prior treatment for their metastatic disease. But because the drug is only effective in those with HER2-positive disease, Herceptin's labeling requires patients to be tested with a newly approved stomach cancer companion diagnostic, noted Genentech spokeswoman Krysta Pellegrino.Complete Story » seekingalpha.com |